Clinical Trial Update: YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial [Phase 1, Phase 2]

View source ↗

Summary

A multicenter open-label Phase 1b/2 trial evaluating YY-20394 in combination with GEMOX for diffuse large B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• GEMOX (gemcitabine + oxaliplatin)
• YY-20394

Snippet

Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd. | Conditions: Diffuse Large B Cell Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN